Valuation: Soleno Therapeutics, Inc.

Market Cap 2.76B 2.37B 2.21B 2.03B 3.8B 264B 3.85B 26.16B 10.2B 133B 10.37B 10.15B 439B P/E 2024
-10.3x
P/E 2025 119x
Enterprise Value 2.31B 1.98B 1.85B 1.69B 3.18B 221B 3.22B 21.87B 8.53B 111B 8.67B 8.48B 367B EV / Sales 2024
-
EV / Sales 2025 10,678,497x
Free-Float
98.88%
Yield 2024 *
-
Yield 2025 -
1 day+0.04%
6 months+34.68%
Current year+14.49%
Current year 29.43
Extreme 29.43
53.01
1 year 29.43
Extreme 29.43
72.99
3 years 3.69
Extreme 3.69
90.32
5 years 0.85
Extreme 0.85
90.32
10 years 0.85
Extreme 0.85
99
Manager TitleAgeSince
President 61 2026-05-14
Treasurer 46 2026-05-14
Director TitleAgeSince
Director/Board Member 61 2026-05-14
Director/Board Member 46 2026-05-14
Date Insider Type Main position Quantity % Market Cap.
5/18/26 Issuer sale

Director

-33,404 0.0647%
5/18/26 Issuer sale

Sr. VP of Clinical Development

-175,523 0.3400%
1/21/26 Free

Chief Financial Officer

61,400 0.1155%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-.--%-22.69%+1,037.55% 2.76B
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.13%+7.54%+50.91%+281.67% 29.23B
Weighted average by Cap. +0.74%+9.39%+57.26%+166.17%

Financials

2024 2025
Net sales - 190.4 163.1 152.61 139.7 262.17 18.22K 265.63 1.8K 703.13 9.15K 714.95 699.4 30.27K
Net income -176M -151M -141M -129M -242M -16.83B -245M -1.67B -649M -8.45B -660M -646M -27.96B 20.89M 17.89M 16.74M 15.33M 28.76M 2B 29.14M 198M 77.14M 1B 78.44M 76.73M 3.32B
Net Debt -266M -228M -213M -195M -366M -25.43B -371M -2.52B -982M -12.78B -998M -976M -42.26B -454M -388M -364M -333M -624M -43.39B -633M -4.29B -1.67B -21.8B -1.7B -1.67B -72.1B
Logo Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder. The Company sells its product primarily to a specialty pharmacy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
  1. Stock Market
  2. Stocks
  3. SLNO Stock